Molecular Partners AG (NAS:MOLN)

$ 5.3 -0.01 (-0.19%) Market Cap: 195.73 Mil Enterprise Value: 38.95 Mil PE Ratio: 0 PB Ratio: 1.10 GF Score: 62/100

Half Year 2024 Molecular Partners AG Earnings Call Transcript
Aug 27, 2024

$6.92 (+11.79%)

Earnings
Full Year 2023 Molecular Partners AG Earnings Call Transcript
Mar 15, 2024

$3.96 (+2.46%)

Earnings
Molecular Partners AG at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Half Year 2023 Molecular Partners AG Earnings Call Transcript
Aug 25, 2023

$6 (+1.89%)

Earnings
Molecular Partners AG at TD Cowen Inc Radiopharmaceutical Innovation Summit (Virtual) Transcript
Jun 20, 2023
Molecular Partners AG at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2023
Full Year 2022 Molecular Partners AG Earnings Call Transcript
Mar 10, 2023

$5.92 (-3.74%)

Earnings
Molecular Partners AG at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Half Year 2022 Molecular Partners AG Earnings Call Transcript
Aug 26, 2022

$6.43 (-7.35%)

Earnings
Full Year 2021 Molecular Partners AG Earnings Call Transcript
Mar 16, 2022

$20.38 (-0.65%)

Earnings
Molecular Partners AG at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2022
Molecular Partners AG Corporate Call Transcript
Jan 10, 2022
Molecular Partners AG to Host Oncology Day (Virtual) Transcript
Dec 15, 2021
Molecular Partners AG at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 10, 2021
Half Year 2021 Molecular Partners AG Earnings Call Transcript
Aug 26, 2021

$19.95 (-0.25%)

Earnings
Molecular Partners AG at Cowen Healthcare Conference (Virtual) Transcript
Mar 02, 2021
Full Year 2020 Molecular Partners AG Earnings Call Transcript
Feb 05, 2021

Earnings
Molecular Partners AG at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Molecular Partners AG - Special Call Transcript
Dec 17, 2020
Molecular Partners AG at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 16, 2020
Half Year 2020 Molecular Partners AG Earnings Call Transcript
Aug 26, 2020

Earnings
Molecular Partners AG - Special Call Transcript
Jun 26, 2020
Full Year 2019 Molecular Partners AG Earnings Call Transcript
Feb 06, 2020

Earnings
Molecular Partners AG at JPMorgan Healthcare Conference Transcript
Jan 16, 2020
Molecular Partners AG - Special Call Transcript
Dec 12, 2019
Half Year 2019 Molecular Partners AG Earnings Call Transcript
Aug 27, 2019

Earnings
Full Year 2018 Molecular Partners AG Earnings Call Transcript
Feb 07, 2019

Earnings

Molecular Partners AG to Host Oncology Day (Virtual) Transcript

Dec 15, 2021 / 01:30PM GMT

Release Date Price: $15.7 (-2.36%)

Transcript

Seth D. Lewis

Molecular Partners AG - SVP of IR, Communications & Strategy

Good morning, and welcome to the Molecular Partners 2021 Oncology Day, Custom-Built Biology for patients. My name is Seth Lewis, Head of Investor Relations. And we're very pleased to have you here with us today as we highlight the recent achievements of our DARPin-based oncology portfolio.

Joining me today are members of our senior management team, including Patrick Amstutz, Chief Executive Officer; Michael Stumpp, Chief Operating Officer; Dani Steiner, Head of Research; Nicolas Leupin, Chief Medical Officer; and Anne Goubier, Head of Biology. We'll also be joined today by our guest speakers and key opinion leaders in the field of AML, Professors, Adrian Ochsenbein and Carsten Riether.

As a reminder, this is being recorded and is available for replay, but the date of this presentation is December 15, 2021. And we will be making several forward-looking statements throughout the presentation, and I would refer you to the latest presentations and disclaimers on our website should anything have changed. With

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.